Abstract-Angiotensin II exerts its physiological effects by activating multiple subtypes of its receptor such as AT 1a -, AT 1b -, and AT 2 -receptors. Because of a high degree of similarity among these G-protein-coupled receptors, it has been difficult to assign diverse physiological actions of angiotensin II through these receptor subtypes. We have developed small interfering RNAs to selectively inhibit the expression of the AT 1a receptor (AT 1a R) subtype. A dsRNA, AT 1 47, was found to be highly selective and efficient in reducing the levels of AT 1a R subtype. Transfection of AT 1a R-expressing CHO cells with dsRNA AT 1 47 resulted in an 80% decrease in the AT 1a R expression. In contrast, dsRNA AT 1 47 showed no significant effects on both AT 1b R and AT 2 R subtypes. A ngiotensin II (Ang II) exerts profound physiological effects on the cardiovascular system by regulating such diverse functions as increases in blood pressure (BP), extracellular fluid volume, hormone secretion, vascular and cardiac remodeling, stimulation of sympathetic nerve activity, and damping of baroreflexes. 1,2 Most, if not all, of these effects are mediated by activation of a single angiotensin receptor subtype (AT 1 R). Since the discovery of 2 subtypes of AT 1 R, AT 1a R, and AT 1b R in rodents, it has been proposed that this diversity of Ang II actions resides in these 2 subtypes. 3 Because AT 1a R and AT 1b R R share 94% sequence similarity, 4 it has been difficult to develop subtype specific antagonists to link AT 1a R and AT 1b R to distinct cardiovascular effects of Ang II. Thus, investigators have relied on the use of genetic targeting of these receptors in mouse models to link them with various phenotypes. 5-8 For example, AT 1a R knockout studies have indicated the role of this receptor in BP regulation, sodium handling, and central dipsogenic responses. 9 However, knockout studies indicate that AT 1b R can partially replace the BP regulatory functions of AT 1a R. 10 These observations indicate that although knockout technology enables us to delineate an overall physiological perspective, it is limited because of the possible expression of compensatory mechanisms during development. Therefore, new and more selective alternatives need to be developed in which the expression of AT 1a R and AT 1b R could be attenuated in adult animals after development.
A ngiotensin II (Ang II) exerts profound physiological effects on the cardiovascular system by regulating such diverse functions as increases in blood pressure (BP), extracellular fluid volume, hormone secretion, vascular and cardiac remodeling, stimulation of sympathetic nerve activity, and damping of baroreflexes. 1, 2 Most, if not all, of these effects are mediated by activation of a single angiotensin receptor subtype (AT 1 R). Since the discovery of 2 subtypes of AT 1 R, AT 1a R, and AT 1b R in rodents, it has been proposed that this diversity of Ang II actions resides in these 2 subtypes. 3 Because AT 1a R and AT 1b R R share 94% sequence similarity, 4 it has been difficult to develop subtype specific antagonists to link AT 1a R and AT 1b R to distinct cardiovascular effects of Ang II. Thus, investigators have relied on the use of genetic targeting of these receptors in mouse models to link them with various phenotypes. [5] [6] [7] [8] For example, AT 1a R knockout studies have indicated the role of this receptor in BP regulation, sodium handling, and central dipsogenic responses. 9 However, knockout studies indicate that AT 1b R can partially replace the BP regulatory functions of AT 1a R. 10 These observations indicate that although knockout technology enables us to delineate an overall physiological perspective, it is limited because of the possible expression of compensatory mechanisms during development. Therefore, new and more selective alternatives need to be developed in which the expression of AT 1a R and AT 1b R could be attenuated in adult animals after development.
We have taken advantage of recent advances in RNA interference (RNAi) technology to determine whether it can be used to selectively silence the expression of these receptor subtypes. 11 Thus, our objective in this study was to determine whether we could identify a double stranded RNA (dsRNA) sequence that is highly effective and selective for the AT 1a R subtype.
Materials and Methods
Complete coding sequence of Rattus rattus AT 1a R (Gen Bank accession number X62295) was used for the selection of target sequences. The sequence was used in the Target Finder and Design Tool provided by Ambion Inc (Austin, Tex). For screening, 3 target sequences spaced throughout the gene were chosen from the list of candidate siRNAs. Selected sequences did not show near-exact matches to any other known sequence on a BLAST search, confirming their sequence specificity to the AT 1a R. Synthetic duplexeddeprotected siRNAs were purchased from Dharmacon Research, Inc (Lafayette, Col). Three 21-bp dsRNA sequences were designated as AT 1 9 (5Ј-AAACAGCTTGGTGGTGGTGATTGTЈ-3) directed to nucleotides 135 to 156, AT 1 39 (5Ј-AACAACTGCCTGAA-CCCTCTG-3Ј) directed to nucleotides 880 to 901, and AT 1 47 (5Ј-AAAGGCCAAGTCCCACTCAAG-3Ј) directed to nucleotides 966 to 987. In addition, a scrambled sequence with no near-exact match to any known sequence, Scr (5Ј-AATGTACTCACTA-CGAGTGCG-3Ј) was designed as control for AT 1 9 , AT 1 39, and AT 1 47 dsRNAs.
Cell Culture and Transfection
Chinese hamster ovary cells (CHO) stably expressing either rat AT 1a R, AT 1b R, or AT 2 R were maintained at 37°C in Ham F12 medium supplemented with 10% fetal bovine serum. Cells were seeded in 12-well plates at a cell density of 1ϫ10 5 cells/well, 24 hours before their use in transfection. Oligofectamine-mediated (Invitrogen Corporation) transfection of the dsRNA was performed after manufacturer's instructions. Briefly, 2 L of oligofectamine was mixed with 8 L/well of OptiMEM (Invitrogen Corporation); similarly, the dsRNA was diluted a final volume of 90 L/well in OptiMEM. Both solutions were incubated at room temperature for 10 minutes, mixed, and further incubated for 10 to 15 minutes. Cells were washed with phosphate-buffered saline (PBS) and 400 L/well of serum-free Ham F12 media added. After transfection complexes were formed, the transfection mixture was added to the cells and incubation continued for 4 hours at 37°C. This was followed by addition of 250 L/well of Ham F12 to 30%. Cells were maintained for 3 days and used for measurements of Ang II binding activity. 
Measurement of [

Semi-Quantitative Reverse Transcription Polymerase Chain Reaction
Total RNA was isolated using 4-PCR RNA isolation kit (Ambion, Austin, Tex) according to the manufacturer's instructions. Polymerase chain reaction (PCR) specific primers for AT 1 R and AT 2 R sequence were obtained from GenoMechanix LLC (Gainesville, Fla). Sequences for these primers were as follows: AT 1 R: sense, 5Ј-TACGCTATGCAGATGGTGATGGG-3Ј; antisense, 5Ј-CTG-GCTGATGGCTGGCTTGG-3Ј; AT 2 R: sense, 5Ј-GCACCAATG-AGTCCGCATTTA-3Ј; antisense, 5Ј-CAGAAAAGGGTAGATA-ACCGATTGG-3Ј. We used as internal control the amplification of 18 rRNA using the primer set provided by on the TaqMan Ribosomal RNA Control Reagents kit (Applied Biosystems, Foster City, Calif). Reverse transcription reactions were performed using 2 g of total RNA in a volume of 100 L. The PCR conditions were: 95°C for 5 minutes after of 30 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute, with a final extension step of 72°C for 10 minutes. The resulting PCR products were subjected to a 2% agarose gel electrophoresis. Bands representing PCR products for the AT 1 and AT 2 R were quantitated and data normalized with PCR bands for 18S rRNA.
Calcium Uptake
Cells were transfected with either dsRNA AT 1 47 or a dsRNA Scr, as described. Two days after transfection, Ang II-stimulated [ 45 Ca 2ϩ ] uptake was tested as described elsewhere. 12 Briefly, cells were 
Statistical Analysis
Data are shown as meanϮSEM. Statistical differences between 2 means were determined by unpaired Student t test.
Results
In the first series of experiments, our objective was to identify target sequences that would trigger a highly efficient and specific silencing of the AT 1 R. For this, we selected 3 dsRNA sequences targeting the 5Ј middle and 3Ј regions of AT 1a R coding sequence.
Of these dsRNAs, 2 (AT 1 9 and AT 1 47) significantly reduced specific Ang II binding in CHO cells that overexpress AT 1 R ( Figure 1A ). These dsRNAs were without effect on Ang II binding in the CHO cells that overexpress AT 2 R ( Figure 1A ). Whereas AT 1 47 was able to decrease binding of Ang II to cells expressing AT 1 R by 95%, AT 1 9 caused a decrease of only 60% ( Figure 1A ). Scrambled dsRNA failed to influence the binding of Ang II. In contrast, the AT 1 39 sequence was found to be nonselective, decreasing the binding of Ang II in both AT 1 R-and AT 2 R-expressing cells ( Figure 1A ). These data indicate that AT 1 47 sequence is the most effective and selective for AT 1 R silencing. Next, we determined the AT 1 R subtype specificity of dsRNA AT 1 47. For this, both AT 1 a and AT 1 b overexpressing cells were transfected with either AT 1 47 or Scr dsRNA. Figure 1B shows that AT 1 47 was able to completely silence AT 1a R subtype with only modest effect on the AT 1b R subtype. Transfection with Scr dsRNA did not influence binding of either receptor (data not shown). This indicated that AT 1 47 was predominantly selective for the AT 1a R subtype.
Next, we characterized the effect of AT 1 47 on AT 1 a R. dsRNA AT 1 Figure 2B ). An 80% decrease in binding was observed within 1 day, followed by a 97% decrease at 2 days after transfection. This level of decrease was maintained for an additional 24 hours. The receptor levels returned to control levels 7 days after transfection. (Figure 3) . Scatchard analyses revealed a 20-fold decrease in the Bmax for AT 1a R in the AT 1 47-treated cells when compared with Scr controls (0.46Ϯ0.01 versus 8.80Ϯ0.46 pmol/mg protein). In contrast, the Kd values for both treatments remained comparable (0.9Ϯ0.09 versus 2.0Ϯ0.30 nmol/L). The observed decrease in the number of AT 1a R was also reflected in a significant decrease in AT 1a R mRNA levels ( Figure 4A ). An 80% decrease in the mRNA was observed 48 hours after transfection ( Figure 4B) .
Finally, we determined the effect of AT 1 47 on Ca 2ϩ uptake. To find out if decreases in AT 1a R-specific binding was associated to a reduction in functional AT 1a R, we determined the effects of dsRNA transfection on Ang IIstimulated calcium uptake. Ang II (100 nmol/L) caused a 54% increase in [ 45 Ca 2ϩ ] uptake in CHO cells expressing AT 1a R. Transfection of these cells with dsRNA Scr did not influence this stimulation and it was comparable to that of nontransfected cells. In contrast, the Ang II-induced increase in [ 45 Ca 2ϩ ] uptake was completely abolished in by dsRNA AT 1 47 transfected cells ( Figure 5 ).
Discussion
The most significant finding of our study is that it establishes, for the first time to our knowledge, that RNAi technology can be used to silence the AT 1a R subtype. This provides us with a powerful tool for elucidating the respective roles of AT 1a R ] uptake demonstrates that at least 1 of the 3 dsRNA targeted for the AT 1a R subtype is selective and efficient in silencing the AT 1a R subtype gene. The dsRNA AT 1 47 is more efficient in reducing AT 1a R numbers compared with its sister subtype, the AT 1b R, despite the fact that these subtypes share 96% similarity. The dsRNA AT 1 47 is highly efficient and produces AT 1a R silencing that lasts for Ϸ3 days. Until now, the popular technology to reduce angiotensin receptors has been the use of antisense oligonucleotides. [13] [14] [15] [16] [17] [18] RNAi technology not only is highly selective for the subtypes of AT 1a R and AT 1b R but also is more effective than antisense oligonucleotides. For example, a previous study 19 demonstrated a reduction of AT 1 R by 57% to 73% with 1 mol/L concentration of AT 1 R-specific antisense oligonucleotides. In contrast, in the present study, a concentration of 100 nmol/L of dsRNA was found to silence AT 1 R by 95% in 48 hours.
The efficacy of the dsRNA 47 to silence AT 1 R in a physiologically relevant cell was confirmed with the use of astroglia cells in primary cultures. Our observations indicated an 80% decrease in AT 1 binding elicited by this dsRNA in these cultures, confirming the validity of the silencing data obtained for the CHO cells.
In summary, our observations demonstrate that RNAi technology can be successfully used to silence 2 closely related genes for Ang II receptors. This provides us with a powerful tool to selectively silence 1 or more subtypes of AT 1 R and to study their role in cardiovascular physiology and pathophysiology in a way that was not previously possible.
Perspectives
Delineating the roles of the AT 1 R subtypes in various cardiovascular functions has been difficult in the past because of lack of selective antagonists or antisense targeting. This study uses RNAi technology and successfully demonstrates the effectiveness of a dsRNA that selectively targets AT 1a R subtype. Thus, our study provides a well-needed tool to dissect AT 1a R functions in vivo. 
